Nplate, Romiplate (romiplostim) Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The nplate, romiplate (romiplostim) market size has grown strongly in recent years. It will grow from $1.33 million in 2025 to $1.45 million in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to limited treatment options for chronic itp, high bleeding risk from low platelet counts, reliance on corticosteroid therapy, clinical success of biologic agents, hospital-based hematology care.

The nplate, romiplate (romiplostim) market size is expected to see strong growth in the next few years. It will grow to $2.03 million in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to rising prevalence of chronic itp, expansion of biologic therapy adoption, improved long-term safety data, growth of specialty care access, patient preference for sustained platelet control. Major trends in the forecast period include growing adoption of thrombopoietin receptor agonists, shift toward long-term itp management, increased focus on chronic autoimmune disorders, expansion of specialty hematology clinics, improved patient monitoring and dosing strategies.

The increasing incidence of cancer is expected to drive the growth of the Nplate and Romiplate (Romiplostim) market in the coming years. Cancer refers to a group of diseases characterized by the uncontrolled growth and spread of abnormal cells in the body. The rising number of cancer cases is influenced by factors such as an aging population, environmental exposures, lifestyle choices including smoking and poor diet, genetic predisposition, and improvements in diagnostic techniques that enable earlier detection. Nplate and Romiplate (Romiplostim) work by stimulating platelet production through the thrombopoietin receptor, helping cancer patients - particularly those undergoing chemotherapy - by reducing the risk of thrombocytopenia, improving platelet counts, enhancing treatment safety, and lowering the need for platelet transfusions. For example, in August 2024, the Australian Institute of Health and Welfare reported that by 2034, Australia is projected to have approximately 209,000 new cancer diagnoses, up from an estimated 169,000 cases in 2024, reflecting population growth and increasing cancer rates. Additionally, cancer is expected to account for roughly 3 out of every 10 deaths in the country in 2024. Therefore, the increasing incidence of cancer is driving the Nplate and Romiplate (Romiplostim) market.

Rising healthcare expenditure is also expected to support the growth of the Nplate and Romiplate (Romiplostim) market. Healthcare expenditure refers to the total resources spent on healthcare goods and services, including personal care, preventive services, and public health activities, aimed at improving health outcomes over a defined period. Healthcare spending is increasing due to factors such as an aging population, prevalence of chronic diseases, advancements in medical technology, high drug costs, inefficient payment models, and growing demand for services. Higher healthcare expenditure enhances access to advanced biologics like Romiplostim for managing chronic conditions such as immune thrombocytopenia (ITP). For instance, in May 2024, the Office for National Statistics, a UK government agency, reported that total healthcare expenditure grew by 5.6% in nominal terms from 2022 to 2023, compared with 0.9% growth in 2022. Additionally, long-term health and social care expenditure increased by 2.8% in real terms in 2022. Consequently, rising healthcare spending is driving the Nplate and Romiplate (Romiplostim) market.

Leading companies in the Nplate and Romiplate (Romiplostim) market are focusing on developing advanced solutions, such as administration kits, to simplify use, accelerate delivery, and improve survival outcomes for patients exposed to acute myelosuppressive doses of radiation. Administration kits provide healthcare providers with the tools needed to deliver Nplate (Romiplostim) quickly and accurately during radiological or nuclear emergencies. For example, in October 2023, BARDA, a US-based government health and human services department, announced support for the development of an administration kit for Nplate (Romiplostim). Under an ongoing Project BioShield contract, BARDA procured additional doses of Nplate to enhance preparedness for radiological emergencies. Healthcare providers can administer Nplate to adult and pediatric patients, including newborns, to improve survival in cases of Hematopoietic Syndrome of Acute Radiation Syndrome (HSARS).

Major companies operating in the nplate, romiplate (romiplostim) market are Novartis AG, Amgen, Intas Pharmaceuticals.

North America was the largest region in the nplate, romiplate (romiplostim) market in 2025. The regions covered in the nplate, romiplate (romiplostim) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the nplate, romiplate (romiplostim) market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the nplate and romiplate market by raising costs for imported biologic substances, injection devices, and sterile packaging materials. These increases have affected treatment affordability in hospital and specialty clinic settings. Regions such as asia-pacific and eastern europe show higher sensitivity due to import dependence. On the positive side, tariffs have encouraged regional biologics manufacturing and improved supply chain robustness for chronic hematology therapies.

The nplate, romiplate (romiplostim) market research report is one of a series of new reports that provides nplate, romiplate (romiplostim) market statistics, including nplate, romiplate (romiplostim) industry global market size, regional shares, competitors with a nplate, romiplate (romiplostim) market share, detailed nplate, romiplate (romiplostim) market segments, market trends and opportunities, and any further data you may need to thrive in the nplate, romiplate (romiplostim) industry. This nplate, romiplate (romiplostim) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Nplate and Romiplate (romiplostim) are biologic drugs classified as thrombopoietin receptor agonists. They are used to treat immune thrombocytopenia (ITP), a condition in which the immune system destroys platelets, increasing the risk of bleeding. Romiplostim stimulates platelet production in the bone marrow, helping maintain a safe platelet count in patients with chronic ITP.

The main patient groups for Nplate and Romiplate (romiplostim) include pediatric, adult, and geriatric patients. This includes children and adolescents diagnosed with conditions requiring Romiplate treatment, such as chronic ITP. Romiplate promotes platelet production, making it an essential therapy for younger patients with low platelet counts. Pediatric patients may require tailored dosing and careful monitoring due to their developing bodies. Its applications include chronic immune thrombocytopenia, chemotherapy-induced thrombocytopenia, and other related conditions. The medication is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The nplate, romiplate (romiplostim) market consists of sales of the lyophilized powder for injection, nplate 500 mcg, and nplate 125 mcg. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.